Answers are grounded in this paper and cite their sources.
Rapid, single-sample galactomannan assays are increasingly used in haematology, yet direct comparisons remain scarce. This prospective, single-centre exploratory pilot study compared the sōna Aspergillus Galactomannan Lateral Flow Assay (LFA) and the VIRCLIA® Galactomannan Monotest (GM-Monotest) in 45 adults with haematological malignancies, yielding 97 paired serum samples. Reference classification followed the 2020 European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) framework, modified to incorporate GM-Monotest positivity; LFA results did not inform classification. The primary patient-level analysis compared four patients with proven or probable invasive fungal disease (IFD) and 34 with no IFD. Both assays detected the same three reference-positive patients (sensitivity, 75.0%; 95% confidence interval, 30.1–95.4%). Observed specificity was 91.2% for the LFA and 100% for the GM-Monotest; three patients with no IFD were LFA-positive/GM-Monotest-negative, and both assays were negative in one probable case. Cohen’s κ was 0.634 (patient level) and 0.754 (sample level). Excluding GM-Monotest results from the reference classification reduced sensitivity to 50.0% for both assays. These preliminary findings indicate substantial categorical agreement but do not establish diagnostic equivalence; few reference-positive patients and incorporation bias constrain interpretation, particularly for the GM-Monotest. Larger studies using independent reference standards are needed.
No takes yet. Share an insight, caveat, or question.
Berk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: